On this page
Quick Reference
Overview and Recommendations
Background
- •Understand the pathophysiology as a multi-stage cascade beginning with calcium dysregulation in pancreatic acinar cells. This leads to the premature conversion of trypsinogen to active trypsin, causing cellular autodigestion and the release of damage-associated molecular patterns (DAMPs) that trigger (SIRS).
- •Distinguish between the two clinical phases of the disease: the Early Phase (first week), dominated by the host's systemic inflammatory response and potential early organ failure, and the Late Phase (beyond one week), characterized by local complications such as peripancreatic fluid collections and persistent systemic inflammation.
- •Classify severity using the Revised Atlanta Classification (RAC), which categorizes AP into Mild (no organ failure or complications), Moderately Severe (transient organ failure < 48 hours or local/systemic complications), and Severe (persistent organ failure > 48 hours).
- •Identify the primary etiologies, noting that and biliary sludge account for 40–60% of cases, while alcohol consumption accounts for 20–30%. Metabolic triggers, specifically , become a critical risk when serum levels exceed 1,000 mg/dL (11.3 mmol/L).
- •Recognize the "Enigmatic Triad" of (DKA), hypertriglyceridemia, and acute pancreatitis, where each condition can potentially precipitate the others, complicating the initial diagnostic and metabolic stabilization efforts.
- •Note morphological variants including Interstitial Edematous Pancreatitis (IEP), characterized by diffuse enlargement without necrosis, and Necrotizing Pancreatitis, which involves tissue death of the parenchyma or peripancreatic tissues and carries a higher risk of infection.
Evaluation
- •Suspect acute pancreatitis in any patient presenting with sudden-onset, constant, and severe epigastric pain that often radiates to the back and is described as "boring" or "stabbing." Nausea and vomiting are nearly universal and typically do not relieve the pain.
- •Ask about specific risk factors including alcohol intake, history of symptomatic , recent procedures, and medications such as , , or (gliptins).
- •Examine the patient for signs of SIRS, specifically monitoring for tachycardia (HR > 90 bpm), tachypnea, and fever. Persistent tachycardia over the first 7 days is a strong predictor of mortality and infectious pancreatic necrosis.
- •Perform a thorough abdominal exam to identify guarding or rebound tenderness, which may suggest necrotic collections or an . Look for rare hemorrhagic signs like Cullen’s sign (periumbilical ecchymosis) or Grey Turner’s sign (flank ecchymosis).
- •Order a serum lipase level immediately; a value ≥ 3 times the upper limit of normal is highly suggestive of AP. Note that amylase is less specific and may return to normal more quickly than lipase.
- •Obtain a complete metabolic panel and lipid profile to screen for and assess renal function (creatinine) and liver enzymes (ALT > 150 U/L suggests a biliary etiology).
- •Calculate the Neutrophil-to-Lymphocyte Ratio (NLR) at admission and at 48 hours; a rising or persistently elevated NLR is a low-cost marker for predicting persistent organ failure.
- •Monitor for "Red Flags" indicating the need for ICU escalation, including hypotension unresponsive to initial fluids, altered mental status, or respiratory distress (FVC < 15 mL/kg or rising oxygen requirements).
- •Utilize the Modified Marshall Scoring System to objectively define organ failure across the respiratory (PaO2/FiO2 ratio), renal (serum creatinine), and cardiovascular (systolic blood pressure) systems.
- •Order a contrast-enhanced computed tomography (CECT) scan only if the diagnosis is uncertain or if the patient fails to improve after 48–72 hours, as early imaging may underrepresent the extent of pancreatic necrosis.
- •Screen for on the extensor surfaces of the extremities if hypertriglyceridemic pancreatitis is suspected, and assess for which correlates with worse clinical outcomes.
Management
- •Administer aggressive fluid resuscitation with isotonic crystalloids (Lactated Ringer's is often preferred) at 250–500 mL/h initially, unless cardiovascular or renal contraindications exist. Frequent reassessment of fluid status every 6–12 hours is mandatory to avoid fluid overload.
- •Initiate early enteral nutrition (oral or tube feeding) within 24 hours if tolerated, as it maintains the intestinal barrier and reduces the risk of bacterial translocation and infected necrosis compared to parenteral nutrition.
- •Manage pain aggressively using intravenous opioids (e.g., hydromorphone or fentanyl) or multimodal analgesia; avoid relying solely on NSAIDs in the acute phase due to renal risks.
- •Avoid prophylactic antibiotics in patients with sterile necrosis; antibiotics should be reserved for suspected or confirmed infected necrosis (e.g., new fever, rising WBC, or gas on CT).
- •Administer carbapenems (e.g., Meropenem 1g IV every 8 hours) or quinolones with metronidazole if infected necrosis is confirmed, as these agents have superior pancreatic tissue penetration.
- •Implement the "Step-Up" approach for infected pancreatic necrosis: start with percutaneous or endoscopic ultrasound-guided transluminal drainage (EUS-TD) before considering minimally invasive necrosectomy.
- •Utilize lumen-apposing metal stents (LAMS) for the drainage of walled-off necrosis (WON) to improve drainage efficiency and facilitate early nutritional recovery.
- •Treat severe (TG > 1,000 mg/dL) with an insulin infusion (0.1 units/kg/hour) or plasmapheresis to rapidly lower lipid levels and prevent further acinar injury.
- •Perform a during the same admission for all patients with mild biliary pancreatitis to prevent recurrent attacks; for severe cases, delay surgery until inflammatory collections have stabilized.
- •Monitor Procalcitonin (PCT) levels; a value > 1.0 ng/mL is highly suggestive of pancreatic necrosis and may guide the decision for invasive sampling.
- •Initiate Pancreatic Enzyme Replacement Therapy (PERT) (e.g., Creon 25,000–50,000 units per meal) in patients showing signs of malabsorption or those recovering from necrotizing pancreatitis to manage exocrine insufficiency.
- •Refer patients with persistent organ failure, extensive necrosis, or complex local complications to a tertiary specialized center early (within 24–48 hours) to reduce the risk of progression to SAP.
- •Monitor for pancreatic encephalopathy, characterized by confusion or neurological deficits, which may result from the systemic release of pancreatic enzymes like phospholipase A2.
- •Discharge patients once pain is controlled with oral medications, they can tolerate an oral diet, and systemic inflammatory markers are trending downward. Ensure a follow-up plan for repeat imaging if local collections were present.
Board Review — High Yield
- •Cullen's sign — Periumbilical ecchymosis indicating retroperitoneal hemorrhage/hemorrhagic pancreatitis.
- •Grey Turner's sign — Flank ecchymosis associated with severe necrotizing pancreatitis.
- •Sentinel Loop — A localized ileus of a jejunal loop seen on abdominal X-ray near the inflamed pancreas.
- •Revised Atlanta Classification — Defines severity based on organ failure duration: transient (<48h) vs persistent (>48h).
- •Hypertriglyceridemia — AP risk increases significantly when serum triglycerides exceed 1,000 mg/dL.
- •Step-up approach — The strategy of using percutaneous/endoscopic drainage before surgical necrosectomy for infected necrosis.
- •Pancreatic Encephalopathy — Neurological symptoms caused by circulating pancreatic enzymes and cytokine-mediated neuroinflammation.
- •Iatrogenic triggers — Post-ERCP pancreatitis is a common complication; risk is higher in patients with intrapancreatic fat deposition.
Deep Dive — Evidence Details
Definition, Synonyms, and Classification
- ▸Acute pancreatitis is a heterogeneous inflammatory pancreatic syndrome ranging from self-limited disease to persistent organ failure and death. [106]
- ▸Diagnosis is conventionally based on at least two of three findings: characteristic pain, enzymes greater than **3 times** the upper limit of normal, or characteristic imaging. [106]
- ▸The revised Atlanta Classification defines mild, moderately severe, and severe AP; persistent organ failure for **more than 48 hours** defines severe AP. [108][114][115]
- ▸HTG-AP and PPAP are etiologic or clinical-context labels and should be documented separately from severity. [3][113][117]
- ▸Biomarkers, risk scores, obesity, sarcopenia, vitamin-D status, hyperglycemia, and imaging algorithms may assist prognostication but do not replace outcome-based Atlanta classification. [7][8][9][19][107][108][110][112][115]
Definition
Acute pancreatitis (AP) is an acute inflammatory disorder of the pancreas with a clinically heterogeneous course ranging from a self-limited illness to disease complicated by persistent organ failure, pancreatic or peripancreatic complications, and death. Up to approximately one-third of patients may develop complications, according to the iLATAM-AP guideline overview. [106] In routine clinical practice, the diagnosis is established when at least two of three features are present: characteristic acute upper-abdominal pain, serum lipase or amylase activity exceeding 3 times the upper limit of normal, and imaging findings characteristic of AP. [106]
AP is a clinical syndrome rather than a single etiologic disease. Important etiologic or context-specific labels include biliary AP, alcohol-associated AP, hypertriglyceridemic AP (HTG-AP), drug- or substance-associated AP, and postpancreatectomy acute pancreatitis (PPAP). Multiple-substance exposure—including combinations involving alcohol, tobacco, cannabis, or illicit substances—has been evaluated as a risk factor for AP, but exposure history does not itself define disease severity or establish a distinct Atlanta category. [2]
Synonyms and related terms
Acute pancreatitis, AP, and acute pancreatic inflammation are used as equivalent clinical terms. “Severe acute pancreatitis” (SAP) is commonly used for AP meeting the severe category of the revised Atlanta Classification; it should not be applied solely because of a high enzyme concentration, inflammatory biomarker, or an abnormal early prediction score. [108][112][114][115]
Hypertriglyceridemic acute pancreatitis (HTG-AP) denotes AP attributed to markedly elevated triglycerides. Studies of HTG-AP have classified severity using the revised Atlanta Classification and have examined early triglyceride reduction as a management or prognostic variable; these treatment-related thresholds should not be mistaken for diagnostic thresholds for AP. [113][117]
Postpancreatectomy acute pancreatitis (PPAP) is a postoperative entity defined by the International Study Group for Pancreatic Surgery (ISGPS), particularly after pancreatic resection. Sustained postoperative hyperamylasemia (POH) for at least 48 hours is a pivotal component of the consensus definition, but hyperamylasemia alone is not synonymous with clinically meaningful PPAP. [3][20]D The reported PPAP framework incorporates postoperative clinical findings and characteristic computed-tomography abnormalities in addition to the specified enzyme pattern. [20]D
Severity classification: revised Atlanta framework
The revised Atlanta Classification separates AP into three severity categories: mild, moderately severe, and severe. [108][114][115]
- Mild AP: AP without organ failure and without local or systemic complications. [108][115]
- Moderately severe AP: AP with transient organ failure lasting less than 48 hours, and/or local or systemic complications without persistent organ failure. [108][114]
- Severe AP: AP with persistent organ failure lasting more than 48 hours. Organ failure may involve the respiratory, cardiovascular, or renal system; persistent failure is the defining feature of the severe category. [108][114][118]
This time-based distinction is clinically important: the “gold standard” classification of severe AP requires documentation of organ failure persisting beyond 48 hours, which may delay definitive severity designation during the initial assessment. [114] Consequently, early scores and prediction models—such as BISAP, APACHE II, laboratory indices, cytokine or oxidative-stress markers, and computed-tomography models—are risk-stratification tools rather than replacements for the revised Atlanta outcome-based classification. [107][109][112][114][115]
Classification modifiers and prognostic context
Etiology and severity should be recorded separately. For example, a patient may have HTG-AP or alcohol-associated AP and simultaneously meet mild, moderately severe, or severe criteria. [2][113][117] Obesity, sarcopenia, sarcopenic obesity, vitamin-D deficiency, hyperglycemia, and inflammatory indices such as the platelet-to-lymphocyte ratio or neutrophil-percentage-to-albumin ratio may correlate with severity or outcomes, but none is a formal replacement for the revised Atlanta categories. [7][8][9][19]D[110][112]
The same principle applies to emerging biomarkers and experimental mechanisms. Oxidative-stress markers, immune biomarkers, neuromodulatory pathways, and cytokine-mediated systemic inflammation are being investigated for prognostication or therapeutic development, but heterogeneous severity definitions across studies limit their use as classification standards. [107][109][111][118] Non-contrast CT and automated systems such as APEX-NET may support early AP detection and prediction of mild, moderately severe, or severe disease, but imaging-based prediction should be interpreted alongside the clinical course and documented organ failure. [108]
Practical terminology
For documentation, specify: (1) AP diagnosis, (2) presumed etiology, (3) revised Atlanta severity category, (4) presence or absence of local or systemic complications, and (5) whether organ failure is transient or persistent. This prevents postoperative hyperamylasemia, early biomarker abnormalities, or a high-risk prediction score from being incorrectly recorded as severe AP. [3][7][20]D[107][114][115]
| Category | Defining feature | Documentation implication |
|---|---|---|
| Mild AP | No organ failure and no local or systemic complications. [108][115] | Usually record as mild only after assessment for complications and organ failure. [106][108] |
| Moderately severe AP | Transient organ failure lasting <48 hours and/or local or systemic complications without persistent organ failure. [108][114] | Reassess over time because an initially moderate course may progress. [114][118] |
| Severe AP | Persistent organ failure lasting >48 hours. [108][114] | Specify involved organ system(s) and duration. [114][118] |
| PPAP | Postoperative pancreatitis under the ISGPS consensus framework, with sustained POH for ≥48 hours plus relevant clinical and imaging findings. [3][20]D | Do not equate isolated postoperative hyperamylasemia with PPAP. [3][20]D |
Etiology and Triggering Factors
- ▸The cited evidence supports gallstone disease, severe hypertriglyceridemia, and ERCP-related injury as principal etiologic contexts for AP [120,122,131].
- ▸FCS is a genetic cause of severe hypertriglyceridemia and recurrent AP due to functional lipoprotein-lipase deficiency [123].
- ▸The FCS screening study defined severe hypertriglyceridemia as **>885 mg/dL** [128].
- ▸Current smoking was evaluated as a predictor of recurrence after first-episode HTG-AP [126].
- ▸PEP diagnostic criteria in the cited pediatric study included abdominal pain plus pancreatic enzymes **>3× the upper limit of normal** [137].
Overview
The references supplied for this update support three principal etiologic or triggering contexts for acute pancreatitis (AP): gallstone disease, severe hypertriglyceridemia, and procedure-related pancreatic injury after endoscopic retrograde cholangiopancreatography (ERCP). Additional evidence concerns genetic susceptibility, smoking-related recurrence, body composition, and pediatric endoscopic intervention. The cited studies do not provide a comprehensive frequency ranking of all AP causes; therefore, etiologies not addressed in these references are not expanded here.
Gallstone-related acute pancreatitis
Gallstone disease is a major clinical context for AP in the cited literature. Studies evaluated adults with first episodes of gallstone-related AP and assessed subsequent management with cholecystectomy, ERCP alone, or no intervention [131]. The same study described same-admission cholecystectomy as guideline-recommended for mild gallstone-related AP, although surgery is frequently deferred [131]. Evidence also addressed choledocholithiasis, including ERCP for ductal stone clearance followed by laparoscopic cholecystectomy [133][134].
Gallstone-related triggering may recur when the underlying biliary source is not definitively managed. In a nationwide Swedish cohort, cholecystectomy, ERCP alone, and no intervention were compared for recurrent AP and other gallstone-related complications, with death treated as a competing event [131]. A separate updated systematic review compared cholecystectomy with conservative management for symptomatic uncomplicated gallstones and mild acute cholecystitis, particularly in patients at high surgical risk [121]. Prophylactic biliary stenting after complete stone extraction while awaiting cholecystectomy has also been evaluated, although the cited abstract focuses on recurrent choledocholithiasis and does not establish stenting as a pancreatitis-prevention strategy [124].
Hypertriglyceridemia-associated acute pancreatitis
Severe hypertriglyceridemia is a prominent metabolic trigger in the cited evidence. Hypertriglyceridemia-induced AP is characterized by markedly elevated triglycerides and may cause significant clinical complications [120]. The 2026 evidence base includes systematic reviews of triglyceride-lowering strategies—insulin, therapeutic plasma exchange, heparin, hemofiltration, and conservative treatment—reflecting the clinical importance of rapidly reducing triglyceride concentrations after presentation [120]. A separate meta-analysis evaluated apolipoprotein C-III (apoC3)-targeting antisense oligonucleotides and small-interfering RNA therapies for their effects on triglycerides, apoC3 concentrations, and AP incidence [119].
Familial chylomicronemia syndrome (FCS) is a monogenic form of severe hypertriglyceridemia associated with recurrent AP. It results from functional lipoprotein-lipase deficiency, which makes conventional triglyceride-lowering therapies ineffective [123]. Olezarsen and volanesorsen are targeted apoC-III inhibitors evaluated in FCS [123]. In a hospital-based screening study, severe hypertriglyceridemia was defined as triglycerides >885 mg/dL, and the FCS Clinical Score was used to distinguish probable FCS from multifactorial chylomicronemia syndrome [128]. This threshold should be interpreted as the study’s screening definition rather than a universal diagnostic cutoff [128].
Recurrence is an important consequence of persistent hypertriglyceridemic risk. A multicenter cohort specifically examined current smoking at the index hospitalization as a predictor of recurrence after a first episode of hypertriglyceridemia-induced AP [126]. Another retrospective cohort developed a model for 3-year recurrence using admission clinical and laboratory variables and CT-derived skeletal muscle density [135]. Prospective multicenter research has also focused on early prediction of severe HTG-AP, reflecting the reported tendency of HTG-AP to develop severe disease [136].
Procedure-related triggers: post-ERCP pancreatitis
ERCP is a recognized procedural trigger for AP in the supplied literature. Post-ERCP pancreatitis (PEP) was the primary outcome in a network meta-analysis of 41 trials involving 15,627 patients that compared rectal nonsteroidal anti-inflammatory drugs, aggressive lactated Ringer’s hydration, somatostatin, and combinations [122]. The study assessed both PEP and post-ERCP hyperamylasemia [122]. In pediatric patients with chronic pancreatitis undergoing endoscopic retrograde pancreatic duct drainage, PEP was defined by new or worsened abdominal pain together with amylase or lipase >3× the upper limit of normal, using ESGE 2020 criteria [137].
Patient and procedural characteristics may modify post-ERCP risk. A multicenter retrospective study evaluated visceral adipose tissue and other body-composition parameters as predictors of severe PEP [129]. In children with chronic pancreatitis, a single-center study investigated risk factors for PEP and whether standard versus longer pancreatic-stent exchange intervals affected pancreatitis occurrence [137]. The supplied abstracts do not report the individual independent risk factors or comparative effect estimates, so these findings should not be used to assign causality to a specific body-composition measure or stent interval.
Practical etiologic assessment
For a patient with AP, the references support focused assessment for biliary disease or ductal stones, severe hypertriglyceridemia, inherited chylomicronemia when the phenotype is severe or recurrent, and recent ERCP or pancreatic-duct instrumentation [120][123][128][131][137]. Smoking is supported as a potentially important modifiable predictor of recurrence specifically after HTG-AP, rather than as a proven proximate cause of the index episode in the cited cohort [126].
| Context | Evidence supported by the references | Clinical implication |
|---|---|---|
| Gallstone disease/choledocholithiasis | Cohorts and reviews evaluated gallstone-related AP, ductal stones, ERCP clearance, and cholecystectomy [121][131][133][134] | Investigate biliary disease and address the underlying gallstone source when appropriate [131] |
| Severe hypertriglyceridemia | HTG-AP was evaluated in systematic reviews and prediction cohorts [119][120][130][135][136] | Measure triglycerides and consider genetic chylomicronemia in severe or recurrent disease [120][128] |
| Familial chylomicronemia syndrome | Functional lipoprotein-lipase deficiency causes severe HTG and recurrent AP [123] | Conventional lipid-lowering therapy may be ineffective; targeted apoC-III inhibition has been studied [123] |
| ERCP/pancreatic instrumentation | PEP was assessed after ERCP and pancreatic-duct drainage [122][137] | Recent endoscopic intervention should be considered during etiologic assessment [122][137] |
| Modifiers of recurrence/severity | Smoking was studied for HTG-AP recurrence; visceral adipose tissue for severe PEP [126][129] | These findings indicate risk modification or stratification, not necessarily direct causation [126][129] |
Pathophysiology
- ▸Oxidative stress and inadequate NRF2-mediated antioxidant defense can amplify experimental pancreatic inflammation and injury.[145][155]
- ▸NLR, NPAR, NCI, and GINI are prognostic inflammatory or immune-nutrition indices; they should not be interpreted as proven causal mechanisms.[127][112][144][153]
- ▸Visceral adiposity, hypertriglyceridemia-related lipotoxicity, and insulin resistance are linked to more severe hyperlipidemic or systemic disease phenotypes.[143][146][149]
- ▸Gut dysbiosis and NLRP3-associated intestinal epithelial pyroptosis are emerging components of the gut–pancreas axis, with current mechanistic evidence mainly preclinical.[140][147]
- ▸Sarcopenia, delayed nutrition, cardiovascular comorbidity, and prolonged immobilization reflect host vulnerability and downstream consequences that may influence recovery and mortality.[139][148][150][154]
Overview
Acute pancreatitis (AP) is an inflammatory injury of the exocrine pancreas that can remain localized or progress to systemic inflammation, intestinal-barrier failure, and persistent organ dysfunction. The initiating insult varies by etiology, but the available evidence supports interaction among acinar-cell injury, metabolic and oxidative stress, innate immune activation, microvascular dysfunction, and gut–pancreas signaling.[145][147][150][155]D
Acinar-cell injury, oxidative stress, and innate immunity
Experimental evidence identifies oxidative stress as an important amplifier of pancreatic inflammation. NRF2, the principal transcriptional regulator of antioxidant defenses, exerted a protective role in experimental nonalcoholic and alcohol-mediated AP; pancreas-specific NRF2 ablation worsened disease in mouse and cellular models.[155]D An observational human study assessed protein carbonyls, lipid peroxidation, total antioxidant capacity, reduced glutathione, catalase, inflammatory markers, caspase-3, interleukin-1β, and AIM2 according to radiologic severity, supporting a relationship between redox imbalance, inflammation, and apoptosis, although the design cannot establish causality.[145]
Innate immune activation is further implicated in intestinal injury. In experimental AP and lipopolysaccharide-stimulated intestinal epithelial cells, NLRP3-inflammasome-associated pyroptosis was linked to disruption of epithelial tight junctions and intestinal-barrier dysfunction. Healthy-donor small extracellular-vesicle preparations ameliorated barrier injury through a proposed miR-579-3p/ANXA3 pathway that inhibited NLRP3-related pyroptosis; these findings remain preclinical and are not evidence for clinical treatment.[147]
Systemic inflammation and organ dysfunction
Pancreatic inflammation can become systemic, producing endothelial and microcirculatory disturbance and predisposing to respiratory, renal, hepatic, and other organ dysfunction.[141][152][154] Admission fever was associated in a systematic review and meta-analysis with greater AP severity and mortality, indicating that an early systemic temperature response may reflect a higher inflammatory burden; fever is prognostic rather than proof of a specific mechanism.[141] Retrospective studies similarly associated admission inflammatory indices—including the neutrophil-to-lymphocyte ratio, neutrophil percentage-to-albumin ratio, neutrophil-creatinine index, and global immune-nutrition-inflammation index—with severe AP or complications, but these indices are markers of disease response rather than established causal mediators.[127][144][112][153]
Acute liver injury occurred in 37.7% of 581 retrospectively studied AP inpatients and was associated with the neutrophil-to-lymphocyte ratio after adjustment, supporting a relationship between systemic inflammation and hepatic dysfunction.[127] The neutrophil-creatinine index, calculated as neutrophil count multiplied by serum creatinine, was evaluated as an admission predictor of severe AP against BISAP, APACHE II, Ranson, and HAPS scores; its biological rationale is the combination of inflammatory activation and early renal dysfunction, although retrospective validation limits mechanistic inference.[144] A randomized trial of thoracic epidural analgesia was designed around the hypothesis that improved splanchnic perfusion and attenuated inflammation could reduce acute kidney injury; 80 analyzed patients were randomized to epidural analgesia or standard care, with renal and metabolic parameters monitored using KDIGO criteria.[152]
Metabolic and adipose-tissue mechanisms
Visceral adipose tissue (VAT) is metabolically active and may intensify AP through inflammatory signaling and metabolic dysregulation. A meta-analysis of 13 studies involving 2,917 patients found higher VAT content in patients with moderately severe AP and evaluated its association with disease severity, supporting VAT as a severity-related biological substrate rather than merely an anthropometric correlate.[143] Obesity is characterized by excess adiposity and persistent low-grade systemic inflammation; semaglutide-associated weight reduction in nondiabetic people is mediated principally by appetite suppression, delayed gastric emptying, and reduced energy intake, with possible anti-inflammatory effects, but this evidence does not establish semaglutide as an AP-modifying therapy.[142]
Hypertriglyceridemic AP illustrates a distinct lipotoxic pathway. Familial chylomicronemia syndrome results from deficient functional lipoprotein lipase, causing severe hypertriglyceridemia and recurrent AP; conventional triglyceride-lowering therapies are ineffective in this setting, whereas apoC-III inhibition is a targeted approach.[123] In a retrospective cohort of 433 subjects, a chemical-structure and metabolic-topology graph-learning model distinguished the hyperlipidemic AP phenotype from the background lipidome of hypertriglyceridemia with an AUC of 0.810, suggesting that specific lipid structures or lipotoxic patterns may be more informative than triglyceride concentration alone.[146] In 113 patients with hyperlipidemic AP, the C-reactive-protein–triglyceride–glucose index was investigated as a composite marker integrating inflammation and insulin resistance, mechanisms considered relevant to disease severity.[149]
Gut barrier, nutrition, and host reserve
Gut dysbiosis, intestinal-barrier dysfunction, and pancreatic inflammation are major linked research themes; bibliometric analysis through 2025 documented rapidly expanding investigation of this gut–pancreas axis.[140] Nutritional status may modify systemic stress and recovery: a retrospective study of 1,600 patients evaluated metabolic pathways, inflammatory signaling, gut-barrier markers, and early versus delayed enteral nutrition, with early nutrition defined as ≤48 hours after presentation.[150] Sarcopenia, quantified by the L3 psoas muscle index, was evaluated in 470 patients as a marker of reduced nutritional and physiological reserve and as a predictor of progression to moderately severe or severe AP.[148] Prolonged immobilization in severe AP causes physical deconditioning; a randomized trial of 400 ICU patients tested structured early rehabilitation for functional recovery, quality of life, length of stay, and survival, reflecting the downstream systemic consequences of severe disease rather than its initiating mechanism.[139]
Comorbidity and external triggers
Cardiovascular comorbidity may reduce tolerance to AP-associated systemic inflammation and hemodynamic stress. In a National Inpatient Sample analysis of 1,919,159 AP hospitalizations, atrial fibrillation and cumulative cardiovascular risk-factor burden were evaluated as predictors of in-hospital mortality.[154] A case report described AP temporally associated with COVID-19 pneumonia in a critically ill patient after bronchial artery embolization, illustrating that infection, severe systemic illness, and procedural stress may coexist as potential contributors, but a single case cannot define causation.[151]C
Overall, AP severity appears to arise from the interaction of the initiating pancreatic or metabolic insult with oxidative injury, dysregulated innate immunity, systemic inflammation, microvascular and organ dysfunction, intestinal-barrier failure, metabolic adiposity, and the patient’s nutritional and cardiovascular reserve.[140][143][145][147][148][150][154][155]D
| Domain | Evidence-supported implication |
|---|---|
| Oxidative stress | Redox imbalance correlates with inflammatory and apoptotic activity; NRF2 is protective in experimental AP.[145][155]D |
| Systemic inflammation | Fever and inflammatory indices associate with severity, organ injury, or mortality.[141][127][112][144][153] |
| Metabolic injury | VAT, hypertriglyceridemia, lipotoxic lipid patterns, and insulin resistance are linked to severe disease.[143][123][146][149] |
| Gut barrier | Dysbiosis and NLRP3-related pyroptosis may connect AP with intestinal-barrier failure.[140][147] |
| Host reserve | Nutrition, sarcopenia, cardiovascular disease, and immobilization influence tolerance and recovery.[139][148][150][154] |
History and Physical Examination
- ▸Pain is often the presenting symptom of AP and has prognostic significance; document and reassess it systematically. [156]
- ▸Pain severity may be discordant with pancreatic structural abnormalities in recurrent acute or chronic pancreatitis. [161]
- ▸Assess biliary, metabolic, medication-related, procedural, pregnancy-related, pediatric, and familial causes. [71, 133, 158, 165, 167]
- ▸Consider hypertriglyceridemia, familial chylomicronemia syndrome, and recent asparaginase exposure, particularly when triglycerides exceed **1,000 mg/dL**. [158, 164, 167]
- ▸Assess frailty, sarcopenia, nutritional status, mobility, and early organ dysfunction, especially in older or critically ill patients. [8, 139, 168]
Presenting symptom and pain history
Pain is frequently the presenting symptom of acute pancreatitis (AP) and has prognostic significance; inadequate treatment may adversely affect patient outcomes. [156] The initial history should therefore document onset, duration, progression, location, radiation, severity, functional effect, associated nausea or vomiting, and response to previous analgesia, while reassessing pain serially during admission. [156] Pain intensity may not reliably reflect pancreatic structural abnormalities, particularly in patients with recurrent acute pancreatitis or chronic pancreatitis, because altered peripheral and central pain processing can contribute to symptom severity. [161]C In hospitalized patients, higher serum lipase was associated with increased analgesic use in a retrospective cohort, although this association does not establish that lipase concentration should replace direct pain assessment. [162]
The clinician should establish whether this is a first episode or recurrent disease and ask about previous pancreatitis, chronic abdominal pain, pancreatic procedures, and known pancreatic stones. [161]C A history of recurrent episodes is particularly important because recurrent acute and chronic pancreatitis may be accompanied by persistent or sensitized pain phenotypes whose severity is poorly correlated with structural findings. [161]C
Etiologic history
The history should specifically assess biliary disease, prior gallstones or choledocholithiasis, alcohol exposure, hypertriglyceridemia, diabetes, obesity, hypertension, metabolic syndrome, relevant medications, pregnancy, and recent endoscopic or surgical procedures. [71][133][165]C Biliary pancreatitis during pregnancy requires attention to gestational status, previous biliary symptoms, and prior or planned cholecystectomy or ERCP because both procedures have been evaluated in pregnant patients with biliary AP. [165]C Recent ERCP is relevant because postprocedural pancreatitis is a recognized adverse event after ERCP. [72]
A metabolic history should include known or suspected hypertriglyceridemia, prior episodes of pancreatitis, eruptive xanthomas if present, family history of recurrent pancreatitis or severe lipid disorders, and secondary causes of marked triglyceride elevation. [158][164][167]C Familial chylomicronemia syndrome is an autosomal-recessive disorder caused by pathogenic variants affecting lipoprotein lipase and is characterized by a high risk of life-threatening, recurrent AP. [158] Hypertriglyceridemic pancreatitis may occur in younger patients and has been associated with greater risks of progression to severe disease and recurrence. [164] In children with acute lymphoblastic leukemia, recent asparaginase exposure should be recorded because severe asparaginase-associated hypertriglyceridemia has been reported, including triglyceride concentrations exceeding 1,000 mg/dL. [167]C
Medication reconciliation should include glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide and newer oral agents such as orforglipron, as well as asparaginase and other drugs temporally related to symptom onset. [142][157][163][167]C Observational data in adults with obesity or type 2 diabetes evaluated pancreatic events after GLP-1 RA initiation, including acute and chronic pancreatitis, but these data are not sufficient to establish causation for an individual patient. [163]
Risk stratification from history and general examination
The initial examination should identify features suggesting systemic illness, evolving organ dysfunction, or reduced physiologic reserve, including altered mental status, respiratory distress, hypoxemia, hypotension, tachycardia, oliguria, fever, and inability to tolerate intake; these findings should prompt urgent reassessment and escalation of monitoring. [139][168] Age and baseline vulnerability are clinically relevant: in a cohort of 1,034 adults, outcomes were examined across age groups of 18–40, 41–60, and 61–80 years, with age-related differences considered alongside organ dysfunction and local complications. [168]
The examination should include nutritional and functional assessment, with attention to low body mass, recent weight loss, weakness, reduced mobility, and muscle wasting. [8][139] AP is a catabolic illness, and sarcopenia or sarcopenic obesity has been investigated as a determinant of prolonged hospitalization and other adverse outcomes; studies have assessed skeletal muscle mass, skeletal muscle index, muscle attenuation, and visceral-fat-to-muscle relationships, commonly at the L3 vertebral level. [8] In severe AP requiring intensive care, prolonged immobilization may cause substantial physical deconditioning, supporting early documentation of baseline mobility and functional status. [139]
Abdominal examination should document distension, epigastric or generalized tenderness, guarding, rigidity, bowel-sound abnormalities, and palpable masses, while also assessing for alternative or coexisting intra-abdominal emergencies. [156] Serial examinations are essential because pain, tenderness, systemic instability, and functional decline may evolve during hospitalization. [156][168]
Age-specific and contextual considerations
In children, the history should include feeding tolerance, vomiting, hydration, weight change, and duration of pain; early nutritional intervention has been studied in mild to moderately severe pediatric AP, including comparison of oral and nasogastric feeding. [74] Inflammatory bowel disease is another relevant pediatric context because hyperamylasemia was identified in 18.6% of children in one cohort, emphasizing that an elevated amylase value alone should be interpreted with the clinical presentation rather than treated as synonymous with AP. [160]C In older adults, examination should place particular emphasis on frailty, sarcopenia, comorbidity, baseline cognition, mobility, and early organ dysfunction because age-related vulnerability may influence short-term outcomes. [8][168]
Practical documentation
The history and examination should produce a baseline record of pain severity, analgesic exposure, recurrence pattern, suspected etiology, pregnancy or procedural status, metabolic and medication risks, nutritional reserve, mobility, and systemic or abdominal findings. [156][139][165]C These data support repeated assessment of pain and early recognition of deterioration, particularly in patients with severe hypertriglyceridemia, metabolic syndrome, advanced age, sarcopenia, pregnancy, pediatric disease, or intensive-care-level illness. [71][8][139][164][165]C[168]
| Domain | What to document | Evidence |
|---|---|---|
| Pain | Onset, severity, trajectory, functional effect, analgesic response, and recurrence | [156][161]C[162] |
| Etiology | Biliary disease, hypertriglyceridemia, alcohol, metabolic syndrome, medications, pregnancy, and recent ERCP | [71][72][133][164][165]C |
| Familial/metabolic risk | Recurrent episodes, family history, suspected familial chylomicronemia syndrome, and severe triglyceride elevation | [158][164] |
| Vulnerability | Age, frailty, weight loss, muscle wasting, baseline mobility, and comorbidity | [8][139][168] |
| Context-specific factors | Pediatric feeding tolerance, inflammatory bowel disease, leukemia/asparaginase exposure, and pregnancy | [74][160]C[165]C[167]C |
| Examination | Hemodynamic, respiratory, neurologic, nutritional, functional, and abdominal findings with serial reassessment | [139][156][168] |
Supportive Care and Complication Management
- ▸LR and NS showed no significant difference in overall mortality in a 2026 meta-analysis; fluid dose and rate should be individualized and monitored. [169,181]
- ▸Early enteral nutrition is supported as a physiological strategy in severe AP, whereas the evidence supplied does not define one universal feeding route. [150,171]
- ▸HTG-AP is heterogeneous; LMWH and intensive lipid-lowering decisions should not rely solely on an early triglyceride threshold of **≤5.65 mmol/L within 72 hours**. [113,170]
- ▸Microbiological yield varies by detection method and timing, and gastrointestinal Enterococcus expansion was associated with subsequent infected necrosis. [172,173]
- ▸Splanchnic-vein anticoagulation requires individualized assessment because portomesenteric thrombosis was associated with more bleeding interventions. [175]
- ▸Follow-up after necrotizing AP should assess exocrine function, glycemic status, quality of life, and rehabilitation needs. [178,182]
Fluid resuscitation
Intravenous crystalloid resuscitation remains a central component of early acute pancreatitis (AP) management, but the optimal fluid type, infusion rate, and volume remain uncertain. [169][181] A 2026 systematic review and meta-analysis comparing lactated Ringer’s (LR) with normal saline (NS) found no significant difference in overall mortality between fluids (OR 1.020, 95% CI reported in the study). [169] The review also prespecified systemic inflammatory response syndrome (SIRS), intensive-care transfer, pancreatic necrosis, organ failure, and hospital length of stay as clinically important outcomes. [169] A five-year retrospective study likewise evaluated fluid dose and rate during the first 24 hours after admission, including systemic complications and prognosis, but its observational design limits causal inference. [181] Fluid therapy should therefore be individualized to clinical response and monitored for complications rather than directed by fluid type alone. [169][181]
Nutrition and metabolic support
Nutritional support is particularly important in severe AP because systemic inflammation, metabolic stress, gut-barrier dysfunction, and nutritional status may influence organ failure and mortality. [150] A 2026 updated systematic review with GRADE assessment compared total enteral nutrition (TEN) with total parenteral nutrition (TPN) in severe AP, focusing on infection, organ outcomes, and safety; the rationale for TEN is preservation of gut integrity, whereas TPN may worsen systemic inflammation. [171] A separate retrospective cohort of 1,600 patients compared enteral nutrition initiated within 48 hours with delayed nutrition and adjusted for demographic, etiologic, and comorbidity-related factors. [150] These studies support prioritizing early enteral strategies when feasible, while recognizing that the supplied evidence does not establish that every patient can tolerate TEN or define a single feeding route. [150][171]
Hypertriglyceridemic AP (HTG-AP) is heterogeneous, and treatment effects may vary by clinical subphenotype. [170] A prospective cohort of 1,483 patients used latent-class analysis of admission clinical and laboratory variables, with validation in a multicenter randomized trial of 533 patients, to examine differential responses to low-molecular-weight heparin (LMWH). [170] A retrospective study of 345 patients defined early triglyceride-target achievement as triglycerides ≤5.65 mmol/L within 72 hours; no significant differences were observed between target-achieved and non-achieved groups for pancreatic necrosis or hospital outcomes reported in the abstract. [113] These findings do not justify routine LMWH or intensive lipid-lowering treatment solely to achieve an early biochemical threshold without considering phenotype, bleeding risk, and the clinical indication. [113][170]
Necrosis, infection, and drainage
Microbiology of suspected infected pancreatic necrosis evolves with time. [172] In a prospective study of 20 patients undergoing first percutaneous catheter drainage, metagenomic next-generation sequencing detected organisms in 45.0% and conventional culture in 30.0% of drainage-fluid samples. [172] Positivity was specifically compared for drainage performed at ≤14 days versus >14 days from disease onset, emphasizing that pathogen detection depends on timing and method. [172] Antibiotic exposure may also shape risk: among 57 patients with necrotizing pancreatitis followed in a multicenter microbiota cohort, 20 (35%) developed infected necrosis, and gastrointestinal Enterococcus colonization was associated with subsequent infection after adjustment for severity, biliary etiology, and prior antibiotics (rectal HR 4.48, 95% CI 1.51–13.28). [173]
The supplied 2026 studies provide supportive but non-definitive evidence for drainage and minimally invasive intervention. [176][177]C A retrospective study of 469 patients with severe AP developed a mortality-prediction score from a conservative-treatment cohort and evaluated ultrasound-guided percutaneous catheter drainage after propensity matching, yielding 316 balanced patients. [176] A single-center case series described perioperative nursing management in 41 patients undergoing video-assisted retroperitoneal debridement for infected peripancreatic necrosis. [177]C Automated CT volumetry of peripancreatic collections was developed and externally tested in a retrospective multicenter study of 394 patients, but the abstract supplied here does not provide performance estimates or treatment thresholds. [174]
Vascular and abdominal complications
Splanchnic vein thrombosis is an important complication of pancreatitis, particularly in necrotizing disease. [175] In a retrospective series of 529 patients, 73 (13.8%) developed thrombosis; portomesenteric thrombosis was associated with more frequent anticoagulation use and bleeding interventions than splenic-vein thrombosis. [175] Anticoagulation decisions should therefore balance thrombus location, progression or recanalization goals, and hemorrhagic risk. [175] Rare catastrophic complications include pancreaticoportal fistula, which may present with portal-vein thrombosis, septic shock, multiorgan failure, or unusual cutaneous necrosis; these manifestations were documented in a case report and require urgent cross-sectional imaging and multidisciplinary management. [184]C
Long-term and case-specific care
Patients recovering from acute necrotizing pancreatitis may develop exocrine and endocrine pancreatic insufficiency. [178] A prospective six-month study assessed fecal elastase-1, fasting and postprandial glucose, HbA1c, and insulin resistance after necrotizing AP, supporting structured follow-up of digestive and glycemic function. [178] Quality-of-life impairment after open necrosectomy was evaluated in 82 recovered patients using the SF-36 questionnaire, highlighting the need for long-term rehabilitation and patient-reported outcome assessment. [182]C Individual complications may require specialized rescue treatment: a reported carbapenem-resistant Acinetobacter baumannii necrosis with concurrent Enterococcus faecium bacteremia involved persistent organ failure, abdominal compartment syndrome, acute kidney injury requiring continuous renal replacement therapy, and treatment with sulbactam-durlobactam plus tigecycline. [183]C A modified endoscopic nasobiliary-drainage tube successfully drained a pancreatic pseudocyst in a single case, but this evidence is insufficient to establish the technique as standard care. [185]C Mirabilite external dressing combined with abdominal drainage was evaluated retrospectively in 80 severe-AP patients and was associated with faster pain relief, earlier flatus, and changes in intra-abdominal pressure and other outcomes, but baseline differences and nonrandomized treatment allocation limit interpretation. [179] EUS-guided hepaticogastrostomy evidence in the supplied literature concerns malignant biliary obstruction rather than AP and should not be extrapolated to routine pancreatitis care. [125] A cytology case also illustrates that inflammatory or metaplastic pancreatic lesions during AP can mimic malignancy, so definitive cancer-directed surgery should depend on integrated clinical, imaging, endoscopic, and histopathologic assessment. [180]
| Domain | Evidence | Clinical implication |
|---|---|---|
| Fluid choice | LR versus NS: no mortality difference detected | Individualize crystalloid selection and monitor response. [169] |
| Early nutrition | TEN versus TPN systematic review; early versus delayed EN cohort | Favor enteral approaches when feasible, while accounting for tolerance and severity. [150][171] |
| Suspected infected necrosis | mNGS positivity 45.0% versus culture 30.0% in 20 drainage samples | Interpret microbiology in relation to timing and test method. [172] |
| HTG-AP | TG target ≤5.65 mmol/L within 72 h; phenotype-specific LMWH analysis | Avoid assuming uniform benefit from one biochemical or anticoagulant strategy. [113][170] |
| Splanchnic thrombosis | 73/529 patients affected; portomesenteric disease had more bleeding interventions | Balance anticoagulation benefit against hemorrhage risk. [175] |
| Post-necrotizing pancreatitis | Prospective assessment of fecal elastase-1 and glycemic markers over 6 months | Arrange endocrine and exocrine follow-up. [178] |
References
- [1]
Vujasinovic M, Demir IE, Marchegiani G et al.. “International Multidisciplinary Consensus Report on Definitions, Diagnostic Criteria, and Management of Fatty Pancreas: A Joint Statement Endorsed by EPC, APA, EASD, EASL, ESGAR, ESGE, ESP, ESPCG, ESPEN, ESPGHAN, IAP, JPS, KPBA, LAPSG, and UEG.” United European gastroenterology journal (2026). PMID: 41689768 ↗
L1cGUIDELINECited in: Definition, Synonyms, and Classification - [2]
Adeniran EA, Jiang Y, Yadav D et al.. “Multiple substance use and the risk of pancreatitis: a systematic review.” Therapeutic advances in gastroenterology (2025). PMID: 40873658 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [3]
Heo D, Cardoso SA, Cardoso RP et al.. “Clinical implications of postoperative hyperamylasemia and postpancreatectomy acute pancreatitis after pancreatectomy: A systematic review and meta-analysis.” Surgery (2025). PMID: 40435914 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [4]
Kowal MR, Bhatnagar V, Pine J et al.. “Systematic review of peritoneal lavage and dialysis for patients with severe acute pancreatitis.” HPB : the official journal of the International Hepato Pancreato Biliary Association (2025). PMID: 39939210 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [5]
Williamson L, Hao Y, Basnayake C et al.. “Systematic review of treatments for the gastrointestinal manifestations of systemic lupus erythematosus.” Seminars in arthritis and rheumatism (2024). PMID: 39461088 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [6]
Haseef M, Li SCH, Gaitt T et al.. “Hypertriglyceridemia: updates from clinical trials of new agents and real-world registries.” Current opinion in endocrinology, diabetes, and obesity (2026). PMID: 41717773 ↗
L2bTRIAL_NONRANDOMCited in: Definition, Synonyms, and Classification, Etiology and Triggering Factors - [7]
Ibrahim MY, Alhaj MM, Ibrahim AAA et al.. “Association of platelet-lymphocyte ratio with acute pancreatitis severity: systematic review and meta-analysis.” BMC gastroenterology (2025). PMID: 41388444 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [8]
Kuzman M, Joseph N, Nafady R et al.. “Clinical Impact of Sarcopenia and Sarcopenic Obesity in Acute Pancreatitis: A Systematic Review.” ANZ journal of surgery (2026). PMID: 41351308 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification, History and Physical Examination - [9]
Siuka D, Rakuša M, Vodenik A et al.. “Free and Bioavailable Vitamin D Are Correlated with Disease Severity in Acute Pancreatitis: A Single-Center, Prospective Study.” International journal of molecular sciences (2025). PMID: 40565159 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [10]
Yahia Y, Abuodeh J, Chandra P et al.. “Risk Factors for Acute Pancreatitis Following Intragastric Balloon Insertion: A 7-Year Retrospective Cohort Study.” Obesity surgery (2025). PMID: 39806256 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [11]
Blažević N, Trkulja V, Rogić D et al.. “YKL-40 as a risk stratification marker in acute pancreatitis: A prospective study.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2025). PMID: 39638701 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [12]
Guilabert L, Cárdenas-Jaén K, Vaillo-Rocamora A et al.. “Normal saline versus lactated Ringer's solution for acute pancreatitis resuscitation, an open-label multicenter randomized controlled trial: the WATERLAND trial study protocol.” Trials (2024). PMID: 39434191 ↗
L2bTRIAL_NONRANDOMCited in: Definition, Synonyms, and Classification - [13]
Grudzińska E, Gajda M. “Postoperative Acute Pancreatitis After Pancreatic Resections-A Narrative Review and a Diagnostic Algorithm.” Cancers (2025). PMID: 40940873 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [14]
Sato A, Tani A, Mishima Y et al.. “Assessment of two different criteria for post-pancreatectomy acute pancreatitis: a single-center retrospective analysis and literature review.” HPB : the official journal of the International Hepato Pancreato Biliary Association (2025). PMID: 40340215 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [15]
Bouça-Machado T, Araújo Teixeira JP, Rebelo P et al.. “Comparison of acute pancreatitis and acute on chronic pancreatitis: a retrospective cohort study.” European journal of gastroenterology & hepatology (2025). PMID: 39976002 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [16]
Ranjan MK, Neupane P, Maharjan B et al.. “Adverse Events Related to Azathioprine Use in Patients With Inflammatory Bowel Disease: A Real-World Cohort Study.” Gastroenterology research and practice (2026). PMID: 41971243 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [17]
Zhou H, Li W, Yang S et al.. “Prediction of acute pancreatitis severity using NLR, procalcitonin, and CT severity score: A retrospective study.” Medicine (2025). PMID: 40629608 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [18]
Orbelian L, Trembach N, Durleshter V. “The Role of Inflammatory and Hemostatic Markers in the Prediction of Severe Acute Pancreatitis: An Observational Cohort Study.” Recent advances in inflammation & allergy drug discovery (2025). PMID: 39694959 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [19]
Dungan KM, Chinchilli VM, Pichardo-Lowden A et al.. “Hyperglycemia During Acute Pancreatitis and Progression to Early-Onset Diabetes After Recovery: Preliminary Findings From the Diabetes Related to Acute Pancreatitis and Its Mechanisms (DREAM) Study.” Diabetes care (2026). PMID: 41940812 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [20]
Poelsler LH, Bellotti R, Pably D et al.. “Analysis of Different Post-Operative Hyperamylasemia Criteria for Defining Post-Pancreatectomy Acute Pancreatitis After Distal Pancreatectomy-A Retrospective Single-Center Study.” Journal of clinical medicine (2026). PMID: 41827220 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [21]
Emara A, Mansour A, Aboeldahab H et al.. “Efficacy and Safety of Olezarsen in Hypertriglyceridemia: An Updated Meta-Analysis of Randomised Controlled Trials.” Diabetes, obesity & metabolism (2026). PMID: 41943994 ↗
L1aSR_MA_RCTCited in: Etiology and Triggering Factors - [22]
Elbahloul MA, Gamal A, Maihoub O et al.. “Efficacy and Safety of Apolipoprotein C-III Inhibitors in Hypertriglyceridemia: A Network Meta-Analysis of Randomised Controlled Trials.” Diabetes, obesity & metabolism (2026). PMID: 41917770 ↗
L1aSR_MA_RCTCited in: Etiology and Triggering Factors - [23]
Rehman A, Rajdeep D, Mohnkern JD et al.. “Efficacy of Olezarsen in Severe Hypertriglyceridemia and Acute Pancreatitis Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Digestive diseases and sciences (2026). PMID: 41865223 ↗
L1aSR_MA_RCTCited in: Etiology and Triggering Factors - [24]
Peterson AL, Ashraf AP, Bachman J et al.. “Screening, Diagnosis, and Management of Pediatric Hypertriglyceridemia: A Scientific Statement From the American Heart Association.” Arteriosclerosis, thrombosis, and vascular biology (2026). PMID: 41705332 ↗
L1cGUIDELINECited in: Etiology and Triggering Factors - [25]
Masood A, Qureshi AUH, Khalid Z et al.. “Efficacy and safety of antisense oligonucleotide therapies targeting APoC-III in patients with severe hypertriglyceridemia: a meta-analysis of randomized controlled trials.” Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace (2026). PMID: 41755797 ↗
L1aSR_MA_RCTCited in: Etiology and Triggering Factors - [26]
Loomba R, de-Madaria E, Afghani E et al.. “Clinical Trial: Plozasiran Prevents Recurrent Pancreatitis in Adults With Very Severe Hypertriglyceridemia-Results of a Post Hoc Analysis of the Phase 3 PALISADE Study.” Alimentary pharmacology & therapeutics (2026). PMID: 41923352 ↗
L2bTRIAL_NONRANDOMCited in: Etiology and Triggering Factors - [27]
Qi S, Wang S, Chen W et al.. “Clinical outcomes of lipid apheresis in hypertriglyceridemia-induced acute pancreatitis: A 10-year triglyceride-stratified retrospective study.” Journal of clinical lipidology (2026). PMID: 41963121 ↗
L2bCOHORTCited in: Etiology and Triggering Factors - [28]
Cerbino B, Süffert LC, Monteiro A et al.. “Intrapancreatic Fat Deposition and Risk of Post-ERCP Pancreatitis: A Systematic Review and Meta-analysis.” Pancreas (2026). PMID: 41668341 ↗
L2aSR_OBSCited in: Etiology and Triggering Factors - [29]
Shi B, Feng J, Hu P et al.. “Clinical Outcomes and Safety of Ureteral Catheter-Assisted Antegrade Guidewire Intubation in the Laparoscopic-Endoscopic Rendezvous Procedure for Cholelithiasis with Choledocholithiasis: A Retrospective Cohort Study.” Therapeutics and clinical risk management (2026). PMID: 41859199 ↗
L2bCOHORTCited in: Etiology and Triggering Factors - [30]
Liu J, Xu H, Huang C et al.. “Admission HDL-C and recurrence risk of hypertriglyceridemia-induced acute pancreatitis: a multicenter cohort study.” Frontiers in nutrition (2026). PMID: 41693951 ↗
L2bCOHORTCited in: Etiology and Triggering Factors - [31]
Dayan-Rosenman D, Diletti-Swenson S, Ghayalod N et al.. “Iatrogenic physiologic opioid dependence masquerading as recurrent acute pancreatitis flares: case series.” Addiction science & clinical practice (2026). PMID: 41680940 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [32]
Maringhini A, Patti R, Maringhini M et al.. “Ursodeoxycholic Acid for the Prevention of Relapse of Pregnancy-Related Acute Gallstone Pancreatitis.” Journal of clinical medicine (2026). PMID: 41976880 ↗
L5OTHERCited in: Etiology and Triggering Factors - [33]
Deng F, Ding L, Du YY et al.. “Low-molecular-weight heparin and respiratory failure in hypertriglyceridemia-associated acute pancreatitis.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2026). PMID: 41968002 ↗
L5OTHERCited in: Etiology and Triggering Factors - [34]
Li Y, Wang Y, Wan X et al.. “Radiomics derived from MRI T2-weighted imaging combined with clinical variables for predicting disease severity in hypertriglyceridemic acute pancreatitis.” Abdominal radiology (New York) (2026). PMID: 41925844 ↗
L5OTHERCited in: Etiology and Triggering Factors - [35]
Sirtl S, Ahmad M, Allawadhi P et al.. “NLRP3 Inflammasome Activation-Induced Acute Papillitis as a Trigger of Acute Pancreatitis - A Novel Mechanism of Microlithiasis-Induced Acute Pancreatitis.” United European gastroenterology journal (2026). PMID: 41830600 ↗
L5OTHERCited in: Etiology and Triggering Factors - [36]
Ozkaya M, Atik I, Ozkaya S et al.. “Incidence and clinical significance of biliary and pancreatic duct variations on magnetic resonance cholangiopancreatography.” Abdominal radiology (New York) (2026). PMID: 41801378 ↗
L5OTHERCited in: Etiology and Triggering Factors - [37]
Faraci S, Rollo G, Alghisi F et al.. “ERCP-based management of pediatric chronic pancreatitis: Results from a retrospective long-term multicentric study.” Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2026). PMID: 41723027 ↗
L5OTHERCited in: Etiology and Triggering Factors - [38]
Liu Z, He Y, Chen Z et al.. “Pleural effusion within 24 h of admission predicts severe hypertriglyceridemia-induced acute pancreatitis and organ failure: retrospective cohort of 296 patients.” Frontiers in medicine (2026). PMID: 41658612 ↗
L5OTHERCited in: Etiology and Triggering Factors - [39]
Peng Q, Long Y, Yang K et al.. “Prognostic analysis of acute pancreatitis due to different etiologies and establishment and validation of an early prediction model.” Lipids in health and disease (2026). PMID: 41645226 ↗
L5OTHERCited in: Etiology and Triggering Factors - [40]
Spoială EL, Oltean C, Vasiliu I et al.. “Multimodal Management of Extreme Hypertriglyceridemia in a Child with Recurrent Pancreatitis: Clinical Challenges and Solutions.” Journal of clinical medicine (2026). PMID: 41598575 ↗
L5OTHERCited in: Etiology and Triggering Factors - [41]
Krajewska A, Tłustochowicz K, Kowalik A et al.. “Comparison of the Clinical Course, Management and Outcomes of Acute Pancreatitis in Aged and Young Patients.” Biomedicines (2026). PMID: 41595672 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, History and Physical Examination - [42]
Chiriac S, Sfarti C, Minea H et al.. “Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography for Bile Duct Stones-Avoiding the Avoidable.” Biomedicines (2026). PMID: 41595627 ↗
L5OTHERCited in: Etiology and Triggering Factors - [43]
Choudhary A, James A, Dahake U et al.. “Therapeutic plasmapheresis in a young infant with severe hypertriglyceridemia: a case report.” Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology (2026). PMID: 41923786 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [44]
Takasu S, Nakagawa M, Matsumoto S. “Autopsy case of a possible enigmatic triad accompanied by black esophagus and Wischnewsky spots.” Legal medicine (Tokyo, Japan) (2026). PMID: 41774981 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [45]
Vega J, Torres B, Maiz A et al.. “Case Report: Conventional therapy versus volanesorsen in two sisters with familial chylomicronemia syndrome.” Frontiers in nutrition (2026). PMID: 41737337 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [46]
Bodnar C, Hughey C, Bodker A et al.. “Milky Plasma, Murky Diagnosis: Urgent Plasma Exchange for Severe Hypertriglyceridemia-Induced Hyperviscosity Without Pancreatitis, but With Myocardial Infarction.” Journal of clinical apheresis (2026). PMID: 41709485 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [47]
Liu T, Cao Z, Lai F et al.. “Case Report: Vincristine-induced acute pancreatitis in pediatric Wilms tumor: first reported case challenging previous risk classifications and proposing vigilant monitoring protocols.” Frontiers in pediatrics (2025). PMID: 41602884 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [48]
Wang Z, Liu Y, Ren P et al.. “A prognostic model based on metabolic indicators for recurrent acute pancreatitis in hypertriglyceridemia patients: a retrospective cohort study.” Annals of medicine (2026). PMID: 41978916 ↗
L2bCOHORTCited in: Etiology and Triggering Factors - [49]
Gondal AN, Ahmed P, Akram F et al.. “Evaluation of Acute Pancreatitis in Patients Receiving Doxycycline Therapy: A Prospective Study.” Cureus (2026). PMID: 41646617 ↗
L2bCOHORTCited in: Etiology and Triggering Factors - [50]
Popa SL, Incze V, Ismaiel A et al.. “Non-Infectious Causes for Elevated Procalcitonin.” Medicina (Kaunas, Lithuania) (2026). PMID: 41901546 ↗
L2aSR_OBSCited in: Pathophysiology - [51]
Yang X, Zhang L, Lin H et al.. “Early oral anti-inflammatory diet in patients with mild acute pancreatitis: study protocol for a randomized controlled trial.” Trials (2026). PMID: 41668182 ↗
L2bTRIAL_NONRANDOMCited in: Pathophysiology - [52]
Yan H, Dang X, Du G et al.. “IL-35, IL-37, and IL-38 in acute pancreatitis: proposed immunopathogenic mechanisms and therapeutic potential.” Frontiers in immunology (2026). PMID: 41737213 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology, Supportive Care and Complication Management - [53]
Tun HN, Rahal O, Figueroa Baez IR et al.. “Heart failure with preserved ejection fraction beyond the heart: exploring the heart-liver-pancreas axis.” ESC heart failure (2026). PMID: 41711215 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [54]
Zhang J, Chen H, Wang Y et al.. “Cell death and its interaction with mitochondrial dysfunction in pathogenesis of acute pancreatitis: a comprehensive review.” Apoptosis : an international journal on programmed cell death (2026). PMID: 41663764 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [55]
Kurt SZE, Kurt E, Isin MS et al.. “The diagnostic value of the systemic immune-inflammation index in acute pancreatitis: a retrospective cohort study.” Irish journal of medical science (2026). PMID: 41926028 ↗
L2bCOHORTCited in: Pathophysiology - [56]
Ma H, Li N, Zhang H et al.. “The association between inflammatory indices and acute pancreatitis severity: a retrospective cohort study.” Frontiers in surgery (2026). PMID: 41835252 ↗
L2bCOHORTCited in: Pathophysiology - [57]
Chooklin S, Chuklin S. “Nanotherapy for acute pancreatitis: a systematic review of experimental strategies and mechanisms of action.” Discover nano (2026). PMID: 41661463 ↗
L2aSR_OBSCited in: Pathophysiology - [58]
Wang Y, Ma L, Jiang Y et al.. “Revealing the temporal metabolic trajectory and potential pharmacodynamic substances of Da-Cheng-Qi Decoction in treating patients with acute pancreatitis: A serum metabolomics-based study.” Journal of ethnopharmacology (2026). PMID: 41825726 ↗
L1bRCTCited in: Pathophysiology - [59]
Alsaleh T, George J. “Targeted therapeutics for pancreatitis.” Frontiers in physiology (2026). PMID: 41907532 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [60]
Chooklin S, Chuklin S. “Beyond Supportive Care: Mitochondria as a Strategic Therapeutic Avenue in Acute Pancreatitis.” Digestive diseases and sciences (2026). PMID: 41854947 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [61]
Chooklin S, Chuklin S. “Interleukin-22 in acute pancreatitis: Balancing damage and repair.” Hepatobiliary & pancreatic diseases international : HBPD INT (2026). PMID: 41763954 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [62]
Chooklin S, Chuklin S. “Breaking the Calcium Overload Cycle in Acute Pancreatitis: Emerging Pharmacological Strategies.” Digestive diseases and sciences (2026). PMID: 41703270 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [63]
Dai NN, Geng ZG, Wang J et al.. “Pancreas-brain axis: exploring the pathogenic mechanisms of pancreatic encephalopathy.” International immunopharmacology (2026). PMID: 41689875 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [64]
Feng X, Lin J. “Advances in Glucocorticoid Therapy for Acute Pancreatitis: A Review.” Pancreas (2026). PMID: 41677367 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [65]
Xu K, Han Y, Chen F et al.. “Dose-dependent dissociation between intestinal protection and pancreatic outcome following licochalcone A treatment in severe acute pancreatitis.” Frontiers in pharmacology (2026). PMID: 41971086 ↗
L5OTHERCited in: Pathophysiology - [66]
Li H, Zhang X, He Z et al.. “Disruption of the Circadian Rhythm Induces Acute Pancreatitis via Amino Acid Metabolism-Mediated Macrophage Infiltration.” Cellular and molecular gastroenterology and hepatology (2026). PMID: 41903683 ↗
L5OTHERCited in: Pathophysiology - [67]
Guan L, Li X, He C et al.. “Bifidobacterium Pseudolongum-Derived Acetate Attenuates Acute Pancreatitis Through GPR43-Mediated Suppression of M1 Macrophage Polarization.” Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2026). PMID: 41903115 ↗
L5OTHERCited in: Pathophysiology - [68]
Uppal M, Neredimelli SK, Yadav HN et al.. “Development of an experimental model of severe acute pancreatitis with organ failure.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2026). PMID: 41881753 ↗
L5OTHERCited in: Pathophysiology, Supportive Care and Complication Management - [69]
Cheng L, Jiang C, Jiang W et al.. “Influences of probiotics plus enteral nutrition on intestinal flora and inflammatory response in patients with severe acute pancreatitis.” Frontiers in medicine (2026). PMID: 41877788 ↗
L5OTHERCited in: Pathophysiology - [70]
Joseph N, Kuhlmann L, Lucocq J et al.. “A Systematic Review of Pain Assessment Domains in Acute Pancreatitis Randomized Controlled Trials.” Pancreas (2026). PMID: 40748823 ↗
L1aSR_MA_RCTCited in: History and Physical Examination - [71]
Dobszai D, Obeidat M, Szalai EÁ et al.. “Metabolic syndrome components individually worsen the outcome of acute pancreatitis: a systematic review and meta-analysis.” Frontiers in endocrinology (2025). PMID: 41262260 ↗
L2aSR_OBSCited in: History and Physical Examination - [72]
Anderloni A, Spadaccini M, Binda C et al.. “Endoscopic Ultrasound-Guided Choledochoduodenostomy vs Endoscopic Retrograde Cholangiopancreatography in Malignant Distal Biliary Obstruction to Prevent Postprocedural Pancreatitis: A Randomized Trial.” Gastroenterology (2026). PMID: 41511419 ↗
L1bRCTCited in: History and Physical Examination - [73]
Gan W, Zhang W, Cai J et al.. “A Multicenter Study of Acute Abdomen in Children With Acute Lymphoblastic Leukemia: CCCG-ALL-2015.” Cancer medicine (2025). PMID: 40842042 ↗
L1bRCTCited in: History and Physical Examination - [74]
Han Y, Zhao H, Fu L et al.. “The utilization of oral feeding in pediatric pancreatitis: a randomized controlled study.” Jornal de pediatria (2026). PMID: 41620210 ↗
L1bRCTCited in: History and Physical Examination - [75]
Wan J, Xiong S, Zou Y et al.. “Cumulative burden and dynamic trajectories of heart rate as predictors of prognosis in acute pancreatitis: an 18-year cohort study.” International journal of surgery (London, England) (2026). PMID: 40990508 ↗
L2bCOHORTCited in: History and Physical Examination - [76]
Kerbage A, Brunaldi VO, Al Annan K et al.. “Impact of Metabolic Surgery on the Severity and Outcomes of Acute Pancreatitis: A Retrospective Matched Cohort Study.” Obesity surgery (2025). PMID: 40804224 ↗
L2bCOHORTCited in: History and Physical Examination - [77]
Palermo TM, Ohls O, Dear B et al.. “Digital cognitive-behavioral therapy for pain management in individuals with recurrent acute and chronic pancreatitis (IMPACT-2): study protocol for a hybrid effectiveness-implementation trial.” Trials (2026). PMID: 41664170 ↗
L2bTRIAL_NONRANDOMCited in: History and Physical Examination - [78]
Jalleh RJ, Talley NJ, Horowitz M et al.. “The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications.” The Journal of clinical investigation (2026). PMID: 41697736 ↗
L5REVIEW_NARRATIVECited in: History and Physical Examination - [79]
Tayier D, Wang K, Yuan Y et al.. “Research Status on the Effects of Obesity on Acute Pancreatitis.” Obesity reviews : an official journal of the International Association for the Study of Obesity (2026). PMID: 40751382 ↗
L5REVIEW_NARRATIVECited in: History and Physical Examination - [80]
Wang YX, Ge P, Chen HL. “Induction of hyperlipidemic pancreatitis by different fatty acids: A narrative review.” World journal of gastroenterology (2025). PMID: 40539203 ↗
L5REVIEW_NARRATIVECited in: History and Physical Examination - [81]
Zhu Q, Shan X, Tan D et al.. “Risk factor analysis and nomogram development for survival prediction in obese patients with severe acute pancreatitis: a retrospective study.” BMC gastroenterology (2025). PMID: 41013263 ↗
L2bCOHORTCited in: History and Physical Examination - [82]
Jaya Pragadeesh G, Abu Sali SA, Rajesh Kumar S et al.. “Gliptin induced acute pancreatitis: a literature review.” Acta gastro-enterologica Belgica (2025). PMID: 40504582 ↗
L2aSR_OBSCited in: History and Physical Examination - [83]
Mohamadnejad M, Hassanzadeh M, Anushirvani A et al.. “Immediate vs On-Demand Endoscopic Necrosectomy in Infected Walled-Off Pancreatic Necrosis: A Randomized Controlled Trial.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2026). PMID: 41722664 ↗
L1bRCTCited in: Supportive Care and Complication Management - [84]
Eperjesi O, Bucur M, Rancz A et al.. “Risk factors for pancreatic exocrine insufficiency after acute pancreatitis: A systematic review and meta-analysis.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2026). PMID: 41807143 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [85]
Chooklin S, Chuklin S. “Neutrophil-to-lymphocyte ratio for primary risk stratification in acute pancreatitis: a systematic review and meta-analysis.” Frontiers in medicine (2025). PMID: 41608433 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [86]
Ren Y, Xia L, Luo L et al.. “Early direct admission to tertiary hospital specialized care reduces risk of severe acute pancreatitis: A propensity score-matched retrospective cohort study.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2026). PMID: 41692636 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [87]
Xu X, He C, Ding L et al.. “The similarity between microbiota of gut and pancreatic necrotic drainage fluid in infected pancreatic necrosis and its potential diagnostic value: a prospective observational cohort study.” BMC microbiology (2026). PMID: 41612182 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [88]
Shahzil M, Faisal MH, Khan MH et al.. “Comparative efficacy and safety of bi-flanged metal stents versus lumen-apposing metal stents for endoscopic drainage of pancreatic fluid collections: a systematic review and meta-analysis.” European journal of gastroenterology & hepatology (2026). PMID: 41925047 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [89]
Shakeev K, Klyuyev D, Ogizbayeva A et al.. “Comparative Evaluation of the Prognostic Accuracy of IL-6 and Angiopoietin-2 for Early Severity Assessment in Acute Pancreatitis: A Systematic Review.” Diseases (Basel, Switzerland) (2026). PMID: 41590239 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [90]
Qi R, Zhong J, Wang H et al.. “Nomogram for Predicting Pancreatic Pseudocyst in Hypertriglyceridemic Acute Pancreatitis: A Retrospective Cohort Study.” Journal of inflammation research (2026). PMID: 41982474 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [91]
Lew C, Jones M, Pham H et al.. “Outcomes of Patients With Severe Acute Pancreatitis Requiring Prolonged Intensive Care Admission at a Tertiary Centre: A Retrospective Cohort Study.” ANZ journal of surgery (2026). PMID: 41823127 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [92]
Cao Y, Li W, Peng P et al.. “Development and validation of an early prediction model for hypertriglyceridaemic severe acute pancreatitis: a retrospective study.” PeerJ (2026). PMID: 41584837 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [93]
Xu H, Zhang Z, Yang Y et al.. “Partial hepatectomy for pancreatic-origin hepatic abscess with intracystic hemorrhage following severe acute pancreatitis: a case report.” Frontiers in medicine (2026). PMID: 41868209 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [94]
Iacob A, Balan GG, Blaj M et al.. “Fungal Infections in Severe Acute Pancreatitis: Insights from a Case Series.” Journal of clinical medicine (2026). PMID: 41598727 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [95]
Tsuyama T, Suenaga S, Suehiro H et al.. “Lumen-apposing metal stent for peripancreatic fluid collection contributes to early improvement of nutritional status: A multicenter retrospective study (YCR-P001).” Medicine (2026). PMID: 41824843 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [96]
Zhang X, Peng K, Peng Y et al.. “Serum GAS6 is useful biomarker for identifying patients with severe acute pancreatitis within 24 h of admission: a multi-cohort analysis of 869 patients.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2026). PMID: 41956867 ↗
L5OTHERCited in: Supportive Care and Complication Management - [97]
Feng H, Wang P, He W et al.. “Development and interpretable machine learning models for classification of pancreatic pseudocyst risk in acute pancreatitis.” Frontiers in digital health (2026). PMID: 41924180 ↗
L5OTHERCited in: Supportive Care and Complication Management - [98]
Zhu P, Fang W, Tu H. “Development and validation of a nomogram model for predicting unplanned readmission in patients with acute pancreatitis.” Frontiers in endocrinology (2026). PMID: 41890191 ↗
L5OTHERCited in: Supportive Care and Complication Management - [99]
Lu H, Shen H, Cui J et al.. “Rhein attenuates severe acute pancreatitis-associated intestinal injury through PPARγ regulating macrophage activation.” Chinese medical journal (2026). PMID: 41859859 ↗
L5OTHERCited in: Supportive Care and Complication Management - [100]
Pauw HS, Schwarz R, Beij A et al.. “Antimicrobial therapy for infected necrotizing pancreatitis: microbiology, antimicrobial resistance and pharmacokinetics.” The Journal of antimicrobial chemotherapy (2026). PMID: 41808660 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [101]
Kitagawa K, Asada S, Hanatani JI et al.. “Multi-Hole Self-Expandable Metallic Stent for Malignant Distal Biliary Obstruction: A Literature Review.” Journal of clinical medicine (2026). PMID: 41753098 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [102]
Fernandez Y Viesca M, Hadefi A, Otero Sanchez L et al.. “Risk Factors Associated with the Emergence of Multidrug-Resistant Bacteria and Fungal Infections in Walled-Off Pancreatic Necrosis.” Antibiotics (Basel, Switzerland) (2026). PMID: 41750517 ↗
L5OTHERCited in: Supportive Care and Complication Management - [103]
Yamashita Y, Kitano M. “EUS-guided pancreatic duct drainage-technical tips and outcomes: narrative review.” Therapeutic advances in gastroenterology (2026). PMID: 41732329 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [104]
Ma S, Qin J, Luan J et al.. “Targeting mitochondrial phosphatase PGAM5 alleviates ferroptosis and acute pancreatitis by upregulating NRF2-mediated FSP1 expression.” Cell death & disease (2026). PMID: 41723122 ↗
L5OTHERCited in: Supportive Care and Complication Management - [105]
Siriwardena AK. “A Practical Guide to the Roles of Procalcitonin Measurement in Patients with Acute Pancreatitis.” Journal of clinical medicine (2026). PMID: 41682834 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [106]
Cárdenas-Jaén K, Guilabert L, Martínez-Moneo E et al.. “AEG-AESPANC-OPGE-SIED-SPG Ibero-Latin American Guidelines on Acute Pancreatitis (iLATAM-AP).” United European gastroenterology journal (2026). PMID: 42216617 ↗
L1aCited in: Definition, Synonyms, and Classification - [107]
Kudchadkar S, Peddakota V, Mudavath LC et al.. “Systematic Review of Role of Oxidative Stress and Clinical Implications in Acute Pancreatitis.” World journal of surgery (2026). PMID: 42438222 ↗
L2aCited in: Definition, Synonyms, and Classification - [108]
Wang F, Huang Z, Xue Z et al.. “APEX-NET: automated pancreatic evaluation network using early non-contrast CT.” European radiology (2026). PMID: 42377437 ↗
L2bCited in: Definition, Synonyms, and Classification - [109]
Madela F, Chiliza K, Mfeka X et al.. “Correlation between immune biomarkers and surrogate markers of severity of Acute Pancreatitis in an HIV endemic region.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2025). PMID: 41314904 ↗
L2bCited in: Definition, Synonyms, and Classification - [110]
Hubert MO, Ahmad M, Crispin A et al.. “Meta-Analysis Obesity Correlates with Severity and Mortality in Acute Pancreatitis: An Updated Meta-Analysis.” Digestive diseases (Basel, Switzerland) (2026). PMID: 42139165 ↗
L2aCited in: Definition, Synonyms, and Classification - [111]
Rantsev M, Sarapultsev A, Chereshnev V. “Neuromodulatory Interventions in Experimental Acute Pancreatitis: A Systematic Review of Rodent Studies.” Diseases (Basel, Switzerland) (2026). PMID: 42041637 ↗
L2aCited in: Definition, Synonyms, and Classification - [112]
Yavuz A, Ebik B, Karabulut Ü et al.. “Evaluation of the Admission Neutrophil Percentage-to-Albumin Ratio for Predicting the Severity of Acute Pancreatitis.” Biomedicines (2026). PMID: 42512016 ↗
L3bCited in: Definition, Synonyms, and Classification - [113]
Yu M, Mao E, Xu Y et al.. “Triglyceride Threshold for Intensive Lipid-Lowering Therapy in Acute Hyper-Triglyceridemic Pancreatitis: A Retrospective Study.” Journal of clinical medicine (2026). PMID: 42355749 ↗
L3bCited in: Definition, Synonyms, and Classification - [114]
Wei W, Wang Y, Xie P et al.. “Development of a prediction method for severe pancreatitis using a nomogram.” Frontiers in medicine (2026). PMID: 42180752 ↗
L3bCited in: Definition, Synonyms, and Classification - [115]
Chiarello MM, Fico V, Misuriello F et al.. “Are BISAP and APACHE II scores still useful to identify high-risk patients in acute pancreatitis? A retrospective multicenter analysis on 450 patients.” Updates in surgery (2026). PMID: 42166093 ↗
L3bCited in: Definition, Synonyms, and Classification - [116]
Hao X, Feng X, Liu F et al.. “Real-time guidance of lauromacrogol ablation for pancreatic cystic lesions using confocal laser endomicroscopy.” Therapeutic advances in gastroenterology (2026). PMID: 41705165 ↗
L3bCited in: Definition, Synonyms, and Classification - [117]
Xu X, Xu T, Wang Y et al.. “Clinical value of BISAP score combined with low-density lipoprotein cholesterol and ascites in early prediction of hypertriglyceridemic severe acute pancreatitis.” Frontiers in endocrinology (2025). PMID: 41446633 ↗
L3bCited in: Definition, Synonyms, and Classification - [118]
Saullo P, Caronna R, Angelici AM et al.. “Value of Continuous Hemofiltration in Patients with Severe Acute Pancreatitis at Onset: Single Centre Experience on 48 Patients.” Journal of clinical medicine (2025). PMID: 41010851 ↗
L3bCited in: Definition, Synonyms, and Classification - [119]
Masson W, Lobo M, Mansur M et al.. “Clinical effects of apolipoprotein C3 inhibitors on triglyceride levels and pancreatitis risk: a systematic review and meta-analysis.” Minerva endocrinology (2026). PMID: 42329673 ↗
L1aCited in: Etiology and Triggering Factors - [120]
Liang AC, Castillo YC, Bruciaga LMM et al.. “Comparative Efficacy of Insulin and Alternative Therapies for Hypertriglyceridemia-Associated Acute Pancreatitis: A Systematic Review and Network Meta-Analysis.” Digestive diseases and sciences (2026). PMID: 42301369 ↗
L1aCited in: Etiology and Triggering Factors - [121]
Gad MM, Ayad Q, Elgamal MM et al.. “Cholecystectomy versus conservative management for patients with uncomplicated symptomatic gallstones and cholecystitis: an updated systematic review and meta-analysis.” BMC surgery (2026). PMID: 42265664 ↗
L1aCited in: Etiology and Triggering Factors - [122]
Shen Y, Bai Y. “Rectal Nonsteroidal Anti-Inflammatory Drugs, Aggressive Hydration With Lactated Ringer's Solution, Somatostatin or Combinations for Prophylaxis Post-ERCP Acute Pancreatitis: A Network Meta-Analysis.” Pancreas (2026). PMID: 42240446 ↗
L1aCited in: Etiology and Triggering Factors - [123]
Soran H, Kessler AS, Vera-Llonch M et al.. “Comparative efficacy and safety of olezarsen versus volanesorsen for familial chylomicronemia syndrome: a matching-adjusted indirect comparison.” Journal of comparative effectiveness research (2026). PMID: 42319369 ↗
L1bCited in: Etiology and Triggering Factors - [124]
Tarar ZI, Gandhi M, Farooq U et al.. “Prophylactic biliary stenting post-ERCP prior to cholecystectomy: a systematic review and meta-analysis.” Surgical endoscopy (2026). PMID: 42443680 ↗
L2aCited in: Etiology and Triggering Factors - [125]
Shaaban Abdelgalil M, Abdelrazek A, Mohamed MS et al.. “EUS-guided hepaticogastrostomy versus EUS-guided hepaticogastrostomy with antegrade stent placement in patients with unresectable malignant distal biliary obstruction: a meta-analysis of individual patient data.” BMC gastroenterology (2026). PMID: 42436411 ↗
L2aCited in: Etiology and Triggering Factors - [126]
Liu J, Yu Y, Qiu X et al.. “Baseline current smoking and time-varying recurrence risk after first-episode of hypertriglyceridemia-induced acute pancreatitis: A multicenter retrospective cohort study.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2026). PMID: 42570923 ↗
L3bCited in: Etiology and Triggering Factors - [127]
Li J, Liu X, Zhao R et al.. “Analysis of the association between the neutrophil-to-lymphocyte ratio (NLR) and liver injury complicating acute pancreatitis: a retrospective study.” Frontiers in medicine (2026). PMID: 42559316 ↗
L3bCited in: Etiology and Triggering Factors - [128]
Ain Q, Huda NU, Khan M et al.. “Prevalence and clinical characteristics of probable familial chylomicronaemia syndrome at a tertiary care center in Pakistan: Insights from a hospital-based screening study.” Journal of clinical lipidology (2026). PMID: 42538190 ↗
L3bCited in: Etiology and Triggering Factors - [129]
Uemura S, Iwashita T, Koizumi T et al.. “Visceral Adipose Tissue as an Independent Predictor of Severe Post-ERCP Pancreatitis: A Multicenter Retrospective Cohort Study.” Journal of hepato-biliary-pancreatic sciences (2026). PMID: 42494284 ↗
L3bCited in: Etiology and Triggering Factors - [130]
Yang S, Li C, Zeng K et al.. “Development and validation of a 24-h predictive model for hypertriglyceridemic moderately severe acute pancreatitis: a single-center retrospective study.” Frontiers in medicine (2026). PMID: 42465082 ↗
L3bCited in: Etiology and Triggering Factors - [131]
Selin D, Oskarsson V, Maret-Ouda J et al.. “Cholecystectomy vs Endoscopic Retrograde Cholangiopancreatography or No Intervention After Gallstone-Related Acute Pancreatitis.” JAMA surgery (2026). PMID: 42340741 ↗
L3bCited in: Etiology and Triggering Factors - [132]
Guo Q, Chen W, Qin K et al.. “Integrating 2.5D multi-modal CT imaging with serum triglycerides for early risk stratification in hypertriglyceridemia-induced acute pancreatitis: A multicenter study.” European journal of radiology (2026). PMID: 42322722 ↗
L3bCited in: Etiology and Triggering Factors - [133]
Liu Z, Li Z, Liu D et al.. “Clinical outcomes of immediate, 24-h, and 24-72-h laparoscopic cholecystectomy after endoscopic stone clearance: a matched cohort analysis.” Surgical endoscopy (2026). PMID: 42257960 ↗
L3bCited in: Etiology and Triggering Factors - [134]
Liu F, Liu XQ, Gu DJ et al.. “Laparoscopic common bile duct exploration and primary suture versus ERCP combined with laparoscopic cholecystectomy for choledocholithiasis: a retrospective comparative study.” Surgical endoscopy (2026). PMID: 42257936 ↗
L3bCited in: Etiology and Triggering Factors - [135]
An J, Zhang G, Zhou X. “A prognostic model based on integrated clinical indicators for recurrent acute pancreatitis in patients with hypertriglyceridemia: a retrospective cohort study.” Lipids in health and disease (2026). PMID: 42249448 ↗
L3bCited in: Etiology and Triggering Factors - [136]
Yao W, Zhao C, Cao L et al.. “Development and Validation of an Early Severity Prediction Model for Hypertriglyceridemia-Associated Acute Pancreatitis: A Multicenter Cohort Study.” Journal of inflammation research (2026). PMID: 42375817 ↗
L2bCited in: Etiology and Triggering Factors - [137]
Zhao G, Wang Y, Zhang G et al.. “Risk factors for post-ERCP pancreatitis and assessment of stent exchange intervals in children with chronic pancreatitis: a single-center retrospective study.” BMC pediatrics (2026). PMID: 42343307 ↗
L2bCited in: Etiology and Triggering Factors - [138]
Nishimura M, Miwa H, Kaneko T et al.. “Post-Endoscopic Retrograde Cholangiopancreatography Bleeding After Endoscopic Stone Removal in Dialysis Patients: A Multicenter Retrospective Study.” DEN open (2026). PMID: 42569438 ↗
L4Cited in: Etiology and Triggering Factors - [139]
Wang L, Nie Z, Huang Q. “Effect of a structured early rehabilitation program on long-term functional recovery, quality of life, and survival in patients with severe acute pancreatitis: a randomized controlled trial.” BMC gastroenterology (2026). PMID: 42204448 ↗
L1bCited in: Pathophysiology - [140]
Tian H, Wang L, He Z et al.. “Global landscape and knowledge structure of research on pancreatitis and gut microbiota: a bibliometric analysis based on WoSCC and Scopus (2006 - 2025).” Frontiers in cellular and infection microbiology (2026). PMID: 42568357 ↗
L2aCited in: Pathophysiology - [141]
Pakai E, Klonfar K, Walter A et al.. “Fever on hospital admission is associated with increased disease severity and mortality in acute pancreatitis: a systematic review and meta-analysis.” Systematic reviews (2026). PMID: 42482129 ↗
L2aCited in: Pathophysiology - [142]
Naz F, Qaiser F, Mumtaz A et al.. “Effectiveness & safety of semaglutide in weight reduction in obese nondiabetic patients: A systematic review and meta-analysis.” Medicine (2026). PMID: 42536519 ↗
L1aCited in: Pathophysiology - [143]
Sang H, Liu X, Song J. “Visceral adipose tissue and acute pancreatitis: a systematic review and meta-analysis.” PeerJ (2026). PMID: 42254660 ↗
L2aCited in: Pathophysiology - [144]
Ben Ismail I, Sghaier M, Zenaidi H et al.. “The Neutrophil-Creatinine Index as an Early Predictor of Severe Acute Pancreatitis.” The Journal of surgical research (2026). PMID: 42556197 ↗
L3bCited in: Pathophysiology - [145]
Pădureanu V, Florescu DN, Cazacu SM et al.. “Evaluation of oxidative stress in acute pancreatitis.” Frontiers in immunology (2026). PMID: 42220490 ↗
L3bCited in: Pathophysiology - [146]
Huang A, Yuan Q, Chen J et al.. “Deep chemical structure graph learning deciphers the lipotoxicity code of hypertriglyceridemic pancreatitis.” NPJ digital medicine (2026). PMID: 42204286 ↗
L3bCited in: Pathophysiology - [147]
Gu H, Tang C, Shi Y et al.. “sEV-Enriched Serum Preparations From Healthy Individuals Protect Against Acute Pancreatitis-Induced Intestinal Barrier Dysfunction Through miR-579-3p/ANXA3-Mediated Inhibition of NLRP3 Inflammasome Pyroptosis.” Archivum immunologiae et therapiae experimentalis (2026). PMID: 42347491 ↗
L3bCited in: Pathophysiology - [148]
Chen X, Li Z, Mao T et al.. “Predictive value of sarcopenia-related clinical indices for early disease progression in acute pancreatitis: a multicenter retrospective cohort study.” Frontiers in nutrition (2026). PMID: 42564036 ↗
L3bCited in: Pathophysiology - [149]
Wen Y, Chen W, Zhang W et al.. “The Correlation Analysis of C-Reactive Protein-Triglyceride-Glucose Index with the Severity of Hyperlipidemic Acute Pancreatitis.” Digestive diseases and sciences (2026). PMID: 42474624 ↗
L3bCited in: Pathophysiology - [150]
Wang Z, Liu Y, Li C. “Nutritional modulation of disease severity in acute pancreatitis: metabolic pathways, inflammatory signaling, and diet-responsive clinical outcomes.” Frontiers in nutrition (2026). PMID: 42459810 ↗
L3bCited in: Pathophysiology - [151]
Yu W, Yang P, Ding M et al.. “Acute pancreatitis temporally associated with COVID-19 pneumonia in a patient with post-tuberculosis chronic pulmonary aspergillosis: a case report.” Frontiers in medicine (2026). PMID: 42344497 ↗
L4Cited in: Pathophysiology - [152]
Ambli S, Gupta BK, Pandey AR et al.. “Comparison of the incidence of acute kidney injury in patients with acute pancreatitis managed with or without thoracic epidural analgesia: A prospective randomized controlled trial.” International journal of critical illness and injury science (2026). PMID: 42281814 ↗
L1bCited in: Pathophysiology - [153]
Turkmen B, Özel Yetkin M, Yenişekerci Kulak E et al.. “The Global Immune-Nutrition-Inflammation Index (GINI) in Acute Pancreatitis Severity Assessment: A Comparative Study.” Digestive diseases and sciences (2026). PMID: 42570998 ↗
L3bCited in: Pathophysiology - [154]
Cohen BD, Eluri N, Levine S et al.. “Atrial fibrillation and cardiovascular comorbidity burden as predictors of in-hospital mortality in acute pancreatitis: A National Inpatient Sample analysis of 1.9 million hospitalizations.” International journal of cardiology. Cardiovascular risk and prevention (2026). PMID: 42382912 ↗
L3bCited in: Pathophysiology - [155]
Mareninova OA, Chang AG, Hernandez Malpica S et al.. “Genetic and pharmacologic modulations elucidate NRF2 protective role in acute pancreatitis.” American journal of physiology. Gastrointestinal and liver physiology (2026). PMID: 42530545 ↗
L5Cited in: Pathophysiology - [156]
Pandanaboyana S, Knoph CS, Kuhlmann L et al.. “European Interdisciplinary Guidelines on Pain Management in Acute Pancreatitis: UEG, EPC, EDS, ESDO, EAGEN, ESPGHAN, ESGAR, and ESPCG Evidence-Based Recommendations.” United European gastroenterology journal (2026). PMID: 42299777 ↗
L1cCited in: History and Physical Examination - [157]
Hammad N, Ramadan AM, Nazmy A et al.. “Efficacy and Safety of Oral GLP-1 RA Orforglipron on Weight and Glycemic Control According to Diabetes Status: A Systematic Review and Meta-Analysis.” Diabetes technology & therapeutics (2026). PMID: 41640110 ↗
L1aCited in: History and Physical Examination - [158]
Aguilar-Salinas CA, Alonso R, Berg G et al.. “A multi-society Delphi consensus statement on the diagnosis of familial chylomicronemia syndrome.” Archives of endocrinology and metabolism (2025). PMID: 41026863 ↗
L1cCited in: History and Physical Examination - [159]
Liu Y, Feng XY, Chen C et al.. “Nutritional recovery after minimally invasive pancreatic stone treatment: Body mass index dynamics and predictors in chronic pancreatitis cohorts.” Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2026). PMID: 42108155 ↗
L2bCited in: History and Physical Examination - [160]
López FV, Kesavan P, Win LK et al.. “Hyperamylasaemia in paediatric inflammatory bowel disease: Aetiology, outcomes and genetic determinants.” Journal of pediatric gastroenterology and nutrition (2026). PMID: 42037072 ↗
L4Cited in: History and Physical Examination - [161]
Kuhlmann L, Davidsen L, Knoph CS et al.. “Trajectories of Pain Processing in Recurrent Acute and Chronic Pancreatitis: A Longitudinal Quantitative Sensory Testing Study.” European journal of pain (London, England) (2026). PMID: 41842672 ↗
L4Cited in: History and Physical Examination - [162]
Gao L, Zhang R, Xiao Y et al.. “High Serum Lipase Level is Associated With Increased Analgesic Use in Hospitalized Patients With Acute Pancreatitis.” Pain research & management (2026). PMID: 41808845 ↗
L3bCited in: History and Physical Examination - [163]
Tartaglia E, Bucci T, Rossi M et al.. “Risk of all-cause death and pancreatic events following GLP-1 RA initiation in people with obesity or type 2 diabetes: observations from a federated research network.” Cardiovascular diabetology (2025). PMID: 41257737 ↗
L3bCited in: History and Physical Examination - [164]
Gu RJ, Zhang YR. “Predictive utility of the triglyceride-glucose index and visceral adiposity-related indices for severe progression in hypertriglyceridemic pancreatitis.” Journal of clinical lipidology (2025). PMID: 41162245 ↗
L3bCited in: History and Physical Examination - [165]
Tarján D, Szalai EÁ, Erőss B et al.. “Safety and Effectiveness of Cholecystectomy and Endoscopic Retrograde Cholangiopancreatography in Biliary Pancreatitis During Pregnancy: BORN Study.” United European gastroenterology journal (2025). PMID: 41045491 ↗
L4Cited in: History and Physical Examination - [166]
Zhou AL, Chiang JY, Chan KS et al.. “Decoding Alexander the Great's gastrointestinal cause of death using artificial wisdom: An artificial intelligence-human inquiry into a medical mystery.” World journal of gastroenterology (2025). PMID: 41479650 ↗
L3bCited in: History and Physical Examination - [167]
Barbar M, Kanaan D, AlZebin Z et al.. “Severe asparaginase-associated hypertriglyceridemia in pediatric acute lymphoblastic leukemia: a single-center experience.” Frontiers in oncology (2026). PMID: 42415868 ↗
L4Cited in: History and Physical Examination - [168]
Yu B, Li Y, Li N et al.. “Age-related vulnerability and clinical outcomes in acute pancreatitis: a stratified cohort study of 1,034 patients.” BMC gastroenterology (2026). PMID: 42304224 ↗
L3bCited in: History and Physical Examination - [169]
Jiang W, Peng J, Wu Q et al.. “Normal saline vs. lactated ringer's for fluid resuscitation in acute pancreatitis: a systematic review and meta-analysis.” Frontiers in medicine (2026). PMID: 42180723 ↗
L1aCited in: Supportive Care and Complication Management - [170]
Ding L, Wang Z, Wang Y et al.. “Hypertriglyceridemic pancreatitis subphenotypes and differential responses to low-molecular-weight heparin: analyses from a cohort and a randomized controlled trial.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2026). PMID: 42420072 ↗
L1bCited in: Supportive Care and Complication Management - [171]
Elzayyat A, Altaie M, Shoaib MI et al.. “Total enteral vs. parenteral nutrition in severe acute pancreatitis: an updated systematic review and GRADE-assessed meta-analysis.” BMC nutrition (2026). PMID: 42087204 ↗
L1aCited in: Supportive Care and Complication Management - [172]
Wu Y, Gao Y, Fang Z et al.. “Time-dependent microbiology of peripancreatic drainage fluid in severe acute pancreatitis: a prospective real-world observational study using metagenomic sequencing and culture.” Frontiers in medicine (2026). PMID: 42328576 ↗
L2bCited in: Supportive Care and Complication Management - [173]
van den Berg FF, Pauw HS, Timmerhuis HC et al.. “Antibiotic-associated Enterococcus expansion in the gastrointestinal tract precedes infected necrosis in acute necrotizing pancreatitis.” Gut microbes (2026). PMID: 42141757 ↗
L2bCited in: Supportive Care and Complication Management - [174]
Ouyang S, Fan Y, Liu F et al.. “Automated CT Volumetry of Peripancreatic Collections for Risk Stratification in Acute Pancreatitis: A Multicenter Retrospective Study.” Academic radiology (2026). PMID: 42567794 ↗
L3bCited in: Supportive Care and Complication Management - [175]
Anandalwar SP, Clark J, Vesselinov R et al.. “Does the risk outweigh the benefit? Clot progression, recanalization & complications of anticoagulation therapy in acute pancreatitis with concomitant splanchnic vein thrombosis.” American journal of surgery (2026). PMID: 42398215 ↗
L3bCited in: Supportive Care and Complication Management - [176]
Long H, Lin J, Zheng R et al.. “Development of a Scoring System For Severe Acute Pancreatitis And Utility of US-guided Catheter Drainage in High-risk Patients.” Academic radiology (2026). PMID: 42161741 ↗
L3bCited in: Supportive Care and Complication Management - [177]
Zhang H, Chen D, Tian H et al.. “Perioperative nursing management in video-assisted retroperitoneal debridement for severe acute pancreatitis with infected peripancreatic necrosis: a retrospective single-center case series of 41 patients.” Frontiers in surgery (2026). PMID: 42369635 ↗
L4Cited in: Supportive Care and Complication Management - [178]
Desai V, Ancil S, Gupta R et al.. “Incidence and Determinants of Pancreatic Insufficiency After Acute Necrotizing Pancreatitis: A Prospective Study.” Digestive diseases and sciences (2026). PMID: 42154122 ↗
L2bCited in: Supportive Care and Complication Management - [179]
Zhang JX, Jin HS, Lu SS et al.. “Potential benefit of mirabilite external dressing combined with abdominal drainage in the early stage of severe acute pancreatitis.” BMC gastroenterology (2026). PMID: 42426625 ↗
L2bCited in: Supportive Care and Complication Management - [180]
Hayashi H, Kubo T, Hara T et al.. “Non-keratinizing immature squamous metaplasia in the pancreas mimicking malignancy: a diagnostic pitfall in cytology.” Journal of pathology and translational medicine (2026). PMID: 42452874 ↗
L3bCited in: Supportive Care and Complication Management - [181]
Lan L, Cheng G, He M et al.. “Fluid resuscitation in the early management of acute pancreatitis: a five-year retrospective observational study.” World journal of emergency medicine (2026). PMID: 42199765 ↗
L3bCited in: Supportive Care and Complication Management - [182]
Gokhe P, Karunakaran M, Gupta S et al.. “QUality of Life After Open Surgical Necrosectomy in Infected Pancreatic Necrosis (QUIP): Defining Targets for Long-Term Follow-up and Interventions.” Digestive diseases and sciences (2026). PMID: 42101798 ↗
L4Cited in: Supportive Care and Complication Management - [183]
Li M, Fu Y, Chen Y et al.. “Case Report: Early documented infected pancreatic necrosis due to carbapenem-resistant Acinetobacter baumannii and concurrent Enterococcus faecium bacteremia: a salvage regimen with sulbactam-durlobactam and tigecycline.” Frontiers in medicine (2026). PMID: 42440864 ↗
L4Cited in: Supportive Care and Complication Management - [184]
Jacq E, Maire F, Cucherousset J et al.. “From Cutaneous Necrosis to Septic Shock: An ICU Case of Pancreatico portal Fistula Complicating Necrotizing Acute Pancreatitis.” Critical care explorations (2026). PMID: 42390290 ↗
L4Cited in: Supportive Care and Complication Management - [185]
Wei H, Sun DY, Wang XY et al.. “Clinical application of self-made ENBD drainage tube in the treatment of pancreatic pseudocyst: a case report.” Frontiers in medicine (2026). PMID: 42221067 ↗
L4Cited in: Supportive Care and Complication Management